Pharsight

Naproxen Sodium is owned by Bionpharma Inc.

Naproxen Sodium contains Naproxen Sodium.

Naproxen Sodium has a total of 5 drug patents out of which 0 drug patents have expired.

Naproxen Sodium was authorised for market use on 17 February, 2006.

Naproxen Sodium is available in capsule;oral dosage forms.

Naproxen Sodium can be used as temporary relief of minor aches and pains; temporary reduction of fever.

The generics of Naproxen Sodium are possible to be released after 03 March, 2026.

Application	Filing Date	Opposition Party	Legal Status
EP06737018A	2017-06-14	Dieckhoff, Beate	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US11090280	July, 2020	Decision	PATHEON SOFTGELS INC
US9693978	January, 2018	Terminated-Denied	Patheon Softgels Inc.	Catalent Pharma Solutions, Inc.
US9693979	January, 2018	Terminated-Denied	Patheon Softgels Inc.	Catalent Pharma Solutions, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028925	BIONPHARMA INC	Liquid dosage forms of sodium naproxen	Mar, 2026 (2 years from now)
US10022344	BIONPHARMA INC	Liquid dosage forms of sodium naproxen	Mar, 2026 (2 years from now)
US11090280	BIONPHARMA INC	Liquid dosage forms of sodium naproxen	Mar, 2026 (2 years from now)
US9693979	BIONPHARMA INC	Liquid dosage forms of sodium naproxen	Mar, 2026 (2 years from now)
US9693978	BIONPHARMA INC	Solvent system for enhancing the solubility of pharmaceutical agents	Mar, 2026 (2 years from now)